Kornimate/medical-research-clean huggingface dataset:
concurrent radiotherapy and/or cisplatin with or without celecoxib in patients with primary oral squamous cell carcinoma

Conditions: Oral Squamous Cell Carcinoma

Summary: the research and development of novel anti-tumor agents in oral cancer is slow, the investigation of repositioning use of currently available drugs in clinical, such as a selective cyclooxygenase-2 (cox-2) inhibitor (celebrex/celecoxib) maybe a potential alternative strategy.

celebrex (celecoxib) is a form of non-steroidal anti-inflammatory drug that directly targets cox-2 enzyme to block the inflammatory signaling and has been approved to treat colon cancer. in our preliminary findings, celecoxib significantly inhibited cell growth,proliferation, migration, invasion and epithelial-mesenchymal transition programs in oral squamous cell carcinoma cell (oscc) lines. the institutional review board in china medical university hospital (cmuh) has approved the combination treatment of concurrent radiotherapy (rt) and/or cisplatin with or without celecoxib in a phase ii clinical trial for relapse-free primary oscc patients.

Eligibility criteria:
inclusion criteria: 1. oscc patients with t1,2/ n0 and without pathological risk features 2. oscc patients with t1,2/ n0,1 and pathological risk features 3. oscc patients with t4a/ n2,3 exclusion criteria: 1. pregnant women paitents 2. taiwanese aboriginal patients 3. not primary oscc patients 4. oscc patients with dysfunction of liver and/or kidneys

Keywords: celecoxib relapse-free oscc patient recurrence survival prognosis
osteoarthrosis on 7.0t magnetic resonance imaging

Conditions: MRI; Osteoarthrosis

Summary: this clinical trial studies the use of 7-tesla (7t)and 3t magnetic resonance imaging (mri) in detecting osteoarthrosis. 7t mri has increased detection sensitivity, including more accurate lesion delineation, higher inter-rater agreement. diagnostic procedures such as 7t mri may help ultimately improved diagnostic and therapies confidence to inform decision making than standard 3t mri.

7t mri increased detection sensitivity, attain superior anatomic resolution, higher spatial and spectral specificity of advanced quantitative techniques, and shorter scan times than 3t mri. when applied clinically, these benefits translate to increased detection sensitivity, and ultimately improved diagnostic and therapies confidence to inform decision making. this study aim to detect the image characteristics and diagnostic accuracy of osteoarthrosis on 7t mri.

Eligibility criteria:
inclusion criteria: * age≥18 and ≤80 * having no contraindications against mri * clinically stable exclusion criteria: * age#18 or #80 * pregnancy and other contraindication to mri scan * informed consent not obtained

Keywords: mri osteoarthrosis
impact of early pcsk9 inhibitor treatment on heart after acute myocardium infarction

Conditions: Acute Myocardial Infarction

Summary: this is a multi-center, prospective, randomized, controlled study. the patients with stemi who were to undergo ppci were divided into pcsk9 inhibitor group (n=80) and conventional treatment group (n=80) using the interactive web response system (iwrs), at a 1:1 ratio. in the pcsk9 inhibitor group, a dose of pcsk9 inhibitor (alirocumab) was injected subcutaneously immediately after ppci and was administered every two weeks thereafter for 3 months; the control group received conventional treatment. cardiac magnetic resonance imaging (mri) were used to measure myocardial salvage index at 1 week after operation as primary endpoints. eject fraction at 6 months after operation will also be measured by mri as secondary endpoints. serum tni/t，ckmb levels were detected q8h for three times and and ldl-c levels were detected at 1 month, 3 months and 6 months after operation. blood inflammation indicators were detected before and 1 week after the operation, and 6 months after the operation.


Eligibility criteria:
inclusion criteria: 1. the age is greater than 18 years old and less than or equal to 80 years old. 2. patients who are clinically diagnosed with stemi onset within 24 hours and who are planning to undergo ppci . 3. signed informed consent. exclusion criteria: 1. patients who are allergic to pcsk9 inhibitors. 2. multivessel disease planned for selective intervention within half a year. 3. patients who have previously undergone revascularization. 4. pregnant women or women who plan to become pregnant in the next 2 years. 5. patients whose life expectancy is less than 1 year. 6. severe liver or kidney dysfunction (alt\>5 times ula, egfr\<15ml/min/1.73m2) 7. known active malignant tumor diseases. 8. patients considered by the investigator to be unsuitable to participate in this study.
evaluation of an intervention to reduce the time to treatment for tavi patients

Conditions: Aortic Valve Stenosis

Summary: aortic stenosis (as) is the most frequent valvulopathy in western countries. the prevalence of as is constantly increasing due to the aging of the population. although significant progress has been made in understanding the pathophysiological mechanisms underlying the onset and progression of as, there is no medical treatment to slow or prevent its progression. the only treatment available is aortic valve replacement (avr) performed by surgery or by catheterization (tavi). once a diagnosis has been made and the decision to treat these patients has been taken, the procedure (avr or tavi) must be performed rapidly given the poor prognosis of the disease without treatment. studies have shown that on the waiting list, the probability of death and hospitalisation for heart failure increases with time. this delay could also reduce the effectiveness of tavi, thus affecting the performance of the healthcare system. in this study, an intervention combining an e-health component (tool intended for patients, families and health professionals in contact with patients), and an organisational component (for tavi implanting centres) has been designed. the aim of this study is to evaluate the effectiveness of this intervention.


Eligibility criteria:
inclusion criteria: * patient over 18 years of age; * aortic stenosis * indication of tavi * patient affiliated or benefiting from a health insurance scheme * patient having read and understood the information letter and having signed the consent form exclusion criteria: * tavi indication not retained * patient who are not fluent in french and have no one around them to translate, * patient who do not have access to the internet (at home or in their immediate environment) * proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of effective contraception (as defined by the who) or postmenopausal woman without confirmation diagnosis obtained (amenorrhea not medically induced for at least 12 months before the initiation visit) ; * person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curators * history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participating in the protocol or preventing him from giving his informed consent

Keywords: aortic stenosis treatment time medico-economy
prevention of opioid misuse and overdose deaths among hispanic/latinx adolescents: a family-based perspective

Conditions: Opioid Misuse

Summary: the purpose of this study is to develop culturally-competent family-focused educational modules targeting opioid knowledge and attitudes (including targeting safe storage and prevention of accidental opioid overdose in adolescent populations) and examine changes acceptability, knowledge, and attitudes scores


Eligibility criteria:
inclusion criteria: * must identify as hispanic/latino/a descent * have an adolescent between the ages of 15 and 17 years old living in their home a majority of the time * have english or spanish proficiency exclusion criteria: * adolescent or parent currently in opioid treatment * parent self-reports a substance use (including opioid use) disorder for themselves or adolescent
cancer-related fatigue during maintenance immunotherapy for non-small cell lung cancer (nsclc): a qualitative study

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this research is to understand cancer related fatigue in patients with non-small cell lung cancer (nsclc), who are being treated with an immune checkpoint inhibitor.

this is an observational pilot study. the target population includes non-dyad caregivers and adult patients diagnosed with inoperable nsclc receiving an immune checkpoint inhibitor and report concerns of fatigue to their provider and caregivers. this study will be conducted at levine cancer institute (lci) and atrium health wake forest baptist comprehensive cancer center (ahwfbccc). this study consists of qualitative interviews at two-time points, the primary, and the follow-up. during the primary interview, patients with nsclc will be asked to complete the promis® fatigue-short form 7a consisting of seven items and caregivers will be asked to complete the cancer caregiving tasks, consequences and needs questionnaire (catcon) form consisting of 5-items in the caregiving workload subscale. during the follow-up interviews, participants will be asked about any change in their fatigue and views on physical activity.

Eligibility criteria:
inclusion criteria: patients: * ≥ 18 years of age at the time of study entry. * patients with inoperable nsclc confirmed by histologic or cytologic documentation and by clinical assessment. * patients have completed at least two cycles of immune checkpoint inhibitors (adjuvant, unresectable, or advanced metastatic disease) as a monotherapy. * if adjuvant or unresectable, immunotherapy must be planned for at least one year. * if advanced metastatic nsclc, immunotherapy must be planned for at least two years. * self-reported cancer or treatment related fatigue as noted in the patient's medical record or per treating physician. * life expectancy of greater than 6 months. caregivers: * 18 years of age at the time of study entry. * a family member or friend helping a patient with nsclc would be eligible for this study in any of the following ways as outlined by the national cancer institute: * helping with day-to-day activities such as doctor visits or preparing food * giving medicines or helping with physical therapy or other clinical tasks * helping with tasks of daily living such as using the bathroom or bathing * coordinating care and services from a distance by phone or email * giving emotional and spiritual support exclusion criteria: patients: * patients who are currently receiving or have received chemotherapy and/or radiation within the past 1 year. * diagnosis of dementia. * history of clinical depression. * current treatment for sarcopenia and anemia or hemoglobin below 10. * untreated hypothyroidism. * symptomatic heart failure. * oxygen dependent lung disease. * cognitively unable to complete interviews. caregivers: - cognitively unable to complete interviews.

Keywords: cancer related fatigue immune checkpoint inhibitor
autonomic nervous system and meridian energy in patients with schizophrenia

Conditions: Schizophrenia; Healthy Individuals

Summary: this study aims to explore the differences in autonomic nervous function and meridian energy between schizophrenia patients and healthy individuals. by understanding the meridian and organ conditions of individuals, the study aims to align with the traditional chinese medicine (tcm) concept of "treating disease before it arises" and provide comprehensive care to patients, thereby improving the quality of care.

data collection was conducted at a medical center in northern taiwan. sample size estimation was performed using g\*power 3.1. a total of 50 patients with schizophrenia were assigned to the disease group, and 50 healthy individuals were assigned to the control group, with a total of 100 participants expected. data collection included: personal demographic questionnaire, body constitution questionnaire (bcq), whoqol-bref (taiwan version) for quality of life, brief psychiatric rating scale (bprs), heart rate variability (hrv), meridian energy

Eligibility criteria:
inclusion criteria: 1. disease group： * diagnosed with schizophrenia by a physician (icd-10 code f20, such as f20.0, f20.1, f20.2, f20.3, f20.5, f20.89, or f20.9), with stable condition, and has not had any changes in medication dosage or admission to a psychiatric acute care unit in the past 3 months. * aged between 18 and 65 years. * able to understand, speak, read, and write mandarin or taiwanese. 2. control group： * no history of chronic illness and no acute symptoms within the past month. * aged between 18 and 65 years. * able to understand, speak, read, and write mandarin or taiwanese. exclusion criteria: 1. disease group： * individuals with cardiovascular conditions, severe neurological disorders (e.g., organic brain disorders, early-stage dementia or diagnosed dementia), or substance abuse issues. * individuals who have used medications affecting the autonomic nervous system within the past month, such as mood stabilizers, antidepressants, angiotensin-converting enzyme inhibitors inhibitors, β-blockers, or antiarrhythmics. * individuals with metallic implants that could affect heart rate variability. * individuals with involuntary and uncontrollable body tremors. * women currently menstruating. * pregnant women. 2. control group： * individuals with cardiovascular conditions, severe neurological disorders (e.g., organic brain disorders, early-stage dementia or diagnosed dementia), or substance abuse issues. * individuals who have used medications affecting the autonomic nervous system within the past month, such as psychiatric medications, angiotensin-converting enzyme inhibitors inhibitors, β-blockers, or antiarrhythmics . * individuals with metallic implants that could affect heart rate variability. * individuals with involuntary and uncontrollable body tremors. * women currently menstruating. * pregnant women.
a study of oral valcyte (valganciclovir) in pediatric kidney transplant recipients

Conditions: Kidney Transplantation, Cytomegalovirus Infections

Summary: this open-label, single arm study will evaluate the tolerability and efficacy of valcyte (valganciclovir) in the prevention of cytomegalovirus disease in pediatric renal transplant recipients. after transplantation, patients (aged 4 months to 16 years) will receive valcyte orally daily for up to 200 days post-transplant and will be followed for 52 weeks post-transplantation.


Eligibility criteria:
inclusion criteria: * children, 4 months to 16 years of age * patient has received a kidney transplant * at risk of developing cytomegalovirus disease * adequate hematological and renal function * able to tolerate oral medication * negative pregnancy test for females of childbearing potential exclusion criteria: * allergic or significant adverse reaction to acyclovir, valacyclovir or ganciclovir in the past * severe uncontrolled diarrhea (more than 5 watery stools per day) * liver enzyme elevation of more than five times the upper limit of normal for aspartate aminotransferase \[ast (sgot)\] or alanine aminotransferase \[alt (sgpt)\] * patient requires use of any protocol prohibited concomitant medication * previous participation in this clinical study
barriers and facilitators of key stakeholders to implement remote monitoring technologies: a mixed-methods analysis

Conditions: COVID-19

Summary: advancements in digital technologies alongside the global pandemic of covid-19 have accelerated the adoption of novel healthcare pathways worldwide, with healthcare delivery transitioning beyond the traditional face-to-face model. telemedicine has gained long over- due exposure during a complicated crisis; as the number of cases continue to grow with second waves predicted, digital modalities have become critical in moderating exposure risk to healthcare staff, reducing community spread, and delivering quality healthcare remotely for exposed or infected individuals. remote monitoring solutions are being established internationally to allow individuals to continue living at home rather than in expensive hospital facilities using non-invasive digital technologies (such as wearable sensors) to collect health data, support health provider assessment and clinical decision making. with the advances in technology miniaturisation, sensors have become increasingly portable, unobtrusive, lightweight, and waterproof, offering an emerging solution to continuous remote monitoring of vital signs. it is predicated that continuous monitoring allows for early recognition of clinical deterioration, and through digital alerting, offers an opportunity for earlier clinical intervention, improving patient care and patient outcomes. within the united kingdom (uk), widespread digital transformations are facilitated by nhs digital, a non-departmental public body created by statute, delivering large health informatics programmes. as such, this study aims to investigate key stakeholder perspectives on an organisational level of implementing remote monitoring solutions, given the pandemic, in the national health service (nhs), identifying factors that could affect successful execution and adoption.


Eligibility criteria:
inclusion criteria: * a mixed methods approach will be implemented: semi-structured interviews will be conducted with high level stake holders from industry, academia, and healthcare providers who have played an instrumental role with prior experience of implementing digital solutions. exclusion criteria: * not able to provide informed consent

Keywords: implementation science
cad/cam angle fracture reduction/plate guide and customized 3d grid plate versus champy's technique

Conditions: Mandibular Fractures

Summary: this proposed study aims at creating a computer designed patient specific device and titanium plates, that are 3d manufactured in accordance to a preoperative computer aided virtual surgical procedure, aiming to obtain proper alignment of fractured segments of the lower jaw and restore proper teeth positioning therefore overcoming the possible complications of the conventional methods. recruited participants will be randomly allocated to a treatment groupp, whether the novel method group or a standard treatment group. preoperative panoramic radiograph and a computed tomography scan will be obtained for each patient. surgical procedure will be conducted unde general anesthetic. medications will be prescribed after surgery and instructions will be given to each patient. follow up will be on a weekly basis for the first 6 weeks followed by a followup visit once a month for 6 months. postoperative panoramic radiograph and a computed tomography scan will be obtained at 1 week after the surgical procrdure and again 6 months later. digital data obtained from computed tomography scans along with clinical data will be analysed and studied to determine the accuracy of the computer aided device and for comparison with the standard method of treatment.


Eligibility criteria:
inclusion criteria: 1. patients with unilateral mandibular angle fracture with or without associated mandibular fractures in need of open reduction and internal fixation. 2. patients above 18 years old 3. sufficient dentition to reproduce the occlusal relationships 4. patient's consent to participate exclusion criteria: 1. patients with comminuted mandibular angle fracture(s) 2. patients with any systemic disease that may affect normal healing 3. patients undergoing chemotherapy or radiotherapy related to the head and neck region 4. intra-bony lesions in the fracture area that may interfere with proper anatomical reduction.
nifedipine pharmacokinetics and pharmacodynamics when used as a tocolytic in acute threatened preterm labour

Conditions: Preterm Labor

Summary: preterm birth is the leading cause of perinatal mortality and morbidity. according to who, 15 million children are born prematurely (gestational age \< 37 weeks) in the world each year while 7% of them die because of complications associated with prematurity. despite constant improvement of obstetrical care, the number of preterm births has increased over the last decades and prematurity is still the most frequent cause of prenatal hospitalization in industrialized countries. the american college of obstetricians and gynecologists as well as the royal college of obstetricians and gynaecologists recommend nifedipine as a first-line tocolytic in case of acute threatened preterm labour. clinical experience show however an important variability in treatment response among pregnant women. in spite of its large use in obstetrics as a tocolytic agent, nifedipine is prescribed off-label. as a consequence no international consensus on optimal dose schedule has so far been proposed. small sample size and heterogeneousness of tocolysis administration protocols make it difficult to compare the little data available on the pharmacokinetics of nifedipine in pregnant women. nevertheless an important interindividual variability in concentrations has been identified (cv=12-76%) but very few studies have investigated the possible reasons of this variability in pregnant women. genetic and environmental factors involved in drug distribution and metabolism (e.g. enzymatic activity, cyp 3a5 genotype) might partially explain variability in drug levels and therefore differences in treatment response. the goal of this study is to quantify the variability in nifedipine pharmacokinetics and identify potential genetic and non-genetic sources of variability in nifedipine pharmacokinetics in pregnant women. the relationship between concentration and treatment response will be evaluated and will serve to propose optimal dosage regimen to improve efficacy and reduce side effects associated with this treatment.


Eligibility criteria:
inclusion criteria: * pregnant women under nifedipine treatment for acute threatened preterm labour * hospitalization for this condition in the maternity of the university hospital of lausanne (chuv) * gestational age of 20-34 weeks * signed informed consent exclusion criteria: * patient \< 18 years * contraindication to tocolysis for clinical reasons (e.g. severe pre-eclampsia, chorioamnionitis, placental anomaly, letal fetal anomaly, important intrauterine growth restriction) or current labour * contraindication to nifedipine * severe renal or hepatic impairment * fever \> 37.5°c * incapacity of communication

Keywords: tocolysis preterm labor nifedipine pharmacokinetics